PDS Biotechnology (NASDAQ:PDSB) versus Appili Therapeutics (OTCMKTS:APLIF) Head to Head Contrast

Appili Therapeutics (OTCMKTS:APLIFGet Rating) and PDS Biotechnology (NASDAQ:PDSBGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Appili Therapeutics and PDS Biotechnology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Appili Therapeutics 0 1 0 0 2.00
PDS Biotechnology 0 0 6 0 3.00

PDS Biotechnology has a consensus price target of $19.50, indicating a potential upside of 248.21%. Given PDS Biotechnology’s stronger consensus rating and higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Appili Therapeutics.

Insider and Institutional Ownership

23.9% of PDS Biotechnology shares are held by institutional investors. 8.3% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Appili Therapeutics has a beta of -2.02, suggesting that its share price is 302% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Valuation & Earnings

This table compares Appili Therapeutics and PDS Biotechnology’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Appili Therapeutics $90,000.00 73.33 -$10.86 million ($0.34) -0.27
PDS Biotechnology N/A N/A -$16.92 million ($0.64) -8.75

Appili Therapeutics has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Appili Therapeutics and PDS Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Appili Therapeutics -1,874.06% -793.06% -203.47%
PDS Biotechnology N/A -37.53% -35.13%


PDS Biotechnology beats Appili Therapeutics on 9 of the 13 factors compared between the two stocks.

Appili Therapeutics Company Profile (Get Rating)

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

PDS Biotechnology Company Profile (Get Rating)

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.